Adcentrx Therapeutics to Showcase Novel STEAP1 and NaPi2b ADCs with Oral and Poster Presentations at AACR 2025

Presentations to highlight preclinical data supporting the clear differentiation of Adcentrx’s clinical-stage ADRX-0405 STEAP1 ADC and preclinical ADRX-0134 NaPi2b ADC SAN DIEGO, March 25, 2025 /PRNewswire/ — Adcentrx Therapeutics (“Adcentrx”), a clinical-stage biotechnology company…